ArticleFrontiers in neurology2026
CT-guided pulsed radiofrequency of sacral and pudendal nerves for herpes zoster-related neurogenic lower urinary tract dysfunction in male patients: a retrospective study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the efficacy of CT-guided pulsed radiofrequency (PRF) neuromodulation targeting the sacral nerves (S2-S4) and the pudendal nerve in male patients with herpes zoster-related neurogenic lower urinary tract dysfunction (NLUTD), a condition lacking effective treatment and significantly impairing quality of life. Materials and methods: A retrospective analysis was conducted on 15 male patients with herpes zoster-related NLUTD who underwent CT-guided PRF treatment between 2024 and 2025. PRF was applied to the sacral nerve roots (S2-S4) and the pudendal nerve. Clinical outcomes were assessed using residual urine volume and Visual Analog Scale (VAS) scores for pain. Most patients received two to three treatment sessions. A 12-week follow-up was conducted, and quality of life was evaluated using the 36-Item Short Form Health Survey (SF-36). Results: PRF treatment resulted in significant and sustained improvements in both urinary function and pain. Residual urine volume decreased markedly from 174.7 ± 43.1 mL at baseline to 29.3 ± 42.2 mL at 12 weeks, while VAS scores declined from 5.8 ± 1.0 to 0.9 ± 1.1. Health-related quality of life also improved significantly, as reflected by reductions in KHQ (73.47 ± 7.17 to 27.27 ± 12.79) and IIQ-7 scores (17.40 ± 1.72 to 5.07 ± 3.01; Conclusion: CT-guided PRF neuromodulation of the sacral and pudendal nerves demonstrates significant therapeutic value for male NLUTD secondary to herpes zoster, providing durable improvements in pain relief, urinary function, and quality of life (SF-36) over a 12-week observation period. The dual neuromodulatory approach is safe and warrants further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.